December 8, 2021 -- Freenome has raised $300 million in series D financing to advance its multiomics platform for early cancer detection. The funding will support the advancement of the company's colorectal cancer screening test and expansion of its multiomics platform to detect other types of cancer.
Freenome's multiomics blood test is being validated in the "Prevention of Colorectal Cancer Through Multiomics Blood Testing" trial, Freenome's large, prospective registrational study, which is currently in the final stages of enrollment.
Financing was led by investors Perceptive Advisors and RA Capital Management. It was joined by existing investors, which included a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, and Soleus Capital Management.